Leerink Partnrs Brokers Increase Earnings Estimates for HIMS

Hims & Hers Health, Inc. (NYSE:HIMS) – Equities researchers at Leerink Partnrs boosted their FY2025 earnings estimates for shares of Hims & Hers Health in a report issued on Tuesday, November 5th. Leerink Partnrs analyst M. Cherny now forecasts that the company will earn $0.49 per share for the year, up from their prior forecast of $0.39. The consensus estimate for Hims & Hers Health’s current full-year earnings is $0.22 per share.

Other analysts have also recently issued research reports about the stock. Piper Sandler reiterated a “neutral” rating and issued a $21.00 price objective (up previously from $18.00) on shares of Hims & Hers Health in a research note on Tuesday. Canaccord Genuity Group raised their price objective on shares of Hims & Hers Health from $24.00 to $28.00 and gave the company a “buy” rating in a research note on Tuesday. Bank of America raised their price objective on shares of Hims & Hers Health from $23.00 to $25.00 and gave the company a “buy” rating in a research note on Monday, October 21st. TD Cowen lifted their target price on shares of Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, July 11th. Finally, Imperial Capital cut shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research report on Friday, August 9th. Eight research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, Hims & Hers Health has a consensus rating of “Moderate Buy” and an average target price of $21.00.

Hims & Hers Health Stock Performance

Shares of Hims & Hers Health stock opened at $23.44 on Thursday. Hims & Hers Health has a 1 year low of $6.58 and a 1 year high of $25.74. The company has a market capitalization of $5.03 billion, a P/E ratio of 53.27 and a beta of 1.06. The company’s fifty day moving average is $18.22 and its two-hundred day moving average is $18.26.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 11.67%. The business had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. During the same period last year, the business earned ($0.04) EPS. The company’s revenue was up 77.1% on a year-over-year basis.

Institutional Investors Weigh In On Hims & Hers Health

A number of institutional investors have recently bought and sold shares of HIMS. CWM LLC grew its stake in Hims & Hers Health by 21.4% during the third quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after buying an additional 1,054 shares during the period. Arizona State Retirement System grew its stake in Hims & Hers Health by 3.0% during the second quarter. Arizona State Retirement System now owns 40,344 shares of the company’s stock worth $815,000 after buying an additional 1,173 shares during the period. Victory Capital Management Inc. grew its stake in Hims & Hers Health by 6.6% during the second quarter. Victory Capital Management Inc. now owns 19,469 shares of the company’s stock worth $393,000 after buying an additional 1,212 shares during the period. Nisa Investment Advisors LLC grew its stake in Hims & Hers Health by 679.2% during the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after buying an additional 1,603 shares during the period. Finally, Swiss National Bank grew its stake in Hims & Hers Health by 0.7% during the first quarter. Swiss National Bank now owns 281,500 shares of the company’s stock worth $4,355,000 after buying an additional 2,000 shares during the period. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, insider Soleil Boughton sold 2,345 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $14.65, for a total value of $34,354.25. Following the completion of the transaction, the insider now owns 159,796 shares of the company’s stock, valued at $2,341,011.40. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, CFO Oluyemi Okupe sold 269,739 shares of the business’s stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $20.31, for a total value of $5,478,399.09. Following the completion of the sale, the chief financial officer now directly owns 145,763 shares in the company, valued at approximately $2,960,446.53. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Soleil Boughton sold 2,345 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $14.65, for a total transaction of $34,354.25. Following the completion of the sale, the insider now owns 159,796 shares of the company’s stock, valued at approximately $2,341,011.40. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 650,659 shares of company stock valued at $11,712,198 over the last 90 days. Insiders own 17.71% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.